[在抗胺β疗法时代对APOE遗传检测的意义和反应]
1Department of Neurology, Gifu University Graduate School of Medicine.
Brain and nerve = Shinkei kenkyu no shinpo
|September 9, 2024
概括
现在建议APOE基因测试用于阿尔茨海默病治疗安全性,但日本面临着将这一关键测试纳入临床实践的挑战.
科学领域:
- 神经遗传学 神经遗传学
- 药物基因组学 药物基因组学
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 传统上,APOE遗传测试不是阿尔茨海默病 (AD) 诊断和管理的一部分.
- 新兴的研究强调了APOE基因定型的重要性,特别是关于抗粉样蛋白-β疗法.
- 目前的美国指导方针要求在给予lecanemab之前进行APOE测试.
研究的目的:
- 突出APOE基因测试在阿尔茨海默病管理中的演变作用.
- 讨论APOE测试对新型抗粉样蛋白疗法的影响.
- 解决与在临床实践中实施APOE测试相关的挑战.
主要方法:
- 关于APOE遗传学和阿尔茨海默病的当前文献的综述.
- 对抗粉样蛋白治疗的最新临床指南的分析.
- 讨论临床,道德,法律和经济方面的考虑.
主要成果:
- APOE遗传测试对于评估抗粉样蛋白治疗的安全性至关重要,如lecanemab.
- 美国的指导方针现在建议对lecanemab进行APOE测试.
- 临床实施面临着巨大的障碍.
结论:
- 将APOE遗传测试纳入常规阿尔茨海默氏症护理中的整合是复杂的.
- 解决临床,伦理,法律和经济方面的挑战对于成功实施至关重要.
- 需要进行全面的讨论,特别是在日本,以解决这些问题.
更多相关视频
07:28Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
3.7K
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.7K
相关概念视频
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
01:26Alzheimer's Disease: Overview
452
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452